A Phase Ib, Double-blind, Clinical Trial to Evaluate the Safety, Tolerability and Immunogenicity of Two Different Dosage Levels of Ebola Chimpanzee Adenovirus Vector Vaccine VRC-EBOAdc069-00-vp (cAd3-EBO) in Healthy Adults, 18-65 Years of Age, in Bamako, Mali
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 19 Apr 2017
At a glance
- Drugs VRC-EBOADC069-00-VP (Primary)
- Indications Ebola virus infections
- Focus Adverse reactions
- 11 Apr 2017 Planned End Date changed from 1 Dec 2016 to 1 Sep 2017.
- 06 Nov 2015 Planned End Date changed from 1 Dec 2015 to 1 Dec 2016, as reported by ClinicalTrials.gov.
- 06 Nov 2015 Planned primary completion date changed from 1 Dec 2015 to 1 Apr 2016, as reported by ClinicalTrials.gov.